Related Experiment Video
Updated: Jul 10, 2026
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
Unmasking hidden high risk in RUNX1::RUNX1T1 pediatric AML: Development of a novel prognostic model
Yang Xun1,2,3,4,5,6, Yali Shen7, Hua Yang1,2,3,4,5,6
1Precision Oncology and Intelligent Theranostics Laboratory, Children's Hospital of Chongqing Medical University, Chongqing, China.
Insights
A new prognostic model for pediatric acute myeloid leukemia (pAML) refines risk stratification using minimal residual disease and blast percentage. It identifies high-risk patients who may benefit from targeted therapies like dasatinib for KIT mutations.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Pediatric acute myeloid leukemia (pAML) with RUNX1::RUNX1T1 fusion is typically favorable risk.
- However, outcome heterogeneity exists, necessitating improved risk stratification.
Purpose of the Study:
- To develop and validate a prognostic model for risk stratification in RUNX1::RUNX1T1-positive pAML.
- To guide individualized therapy decisions for these patients.
Main Methods:
- Analysis of 284 RR+ pAML cases from public datasets (training/validation) and 214 external cases.
- Model development integrating minimal residual disease after induction (MRD1) and peripheral blood blast percentage.
- Assessment of KIT mutations and evaluation of targeted therapies.
Main Results:
- A high-risk subgroup (>30%) with elevated relapse and mortality was identified using MRD1 and blast percentage.
- KIT mutations, especially in exon 17, defined a very-high-risk subset.
- Dasatinib improved survival in the KIT-mutated subset; immune checkpoint modulators and small-molecule inhibitors were identified for other high-risk groups.
Conclusions:
- The developed prognostic model effectively stratifies risk in RR+ pAML.
- It aids in personalized treatment strategies, including targeted therapies for specific genetic mutations.
- This tool supports improved clinical decision-making for pediatric patients with this leukemia subtype.
Abstract:
Although pediatric acute myeloid leukemia (pAML) harboring the RUNX1::RUNX1T1 fusion is generally classified as favorable risk, some patients experience poor outcomes. To address this heterogeneity, we developed and validated a prognostic model to refine risk stratification and guide individualized therapy. We analyzed 284 RR+ pAML cases from public datasets, randomized into training and internal validation cohorts, and assessed generalizability in an independent external cohort of 214 patients from multiple centers in China. The model integrates two readily accessible variables-minimal residual disease after induction (MRD1) and peripheral blood blast percentage at diagnosis-as core predictors. It consistently identified a >30% high-risk subgroup characterized by elevated relapse rates and mortality, who derived limited benefit from transplantation. Furthermore, KIT mutations, particularly in exon 17, delineated a very-high-risk subset with significantly inferior outcomes. In this group, dasatinib treatment was associated with improved overall and event-free survival, whereas no benefit was observed in low-risk patients. For high-risk patients lacking KIT mutations, transcriptional profiling and drug sensitivity analysis identified potential therapeutic candidates, including immune checkpoint modulators (e.g., targeting TLR3 and CD200) and small-molecule inhibitors. This stratification tool provides a simple framework for individualized risk assessment and offers actionable evidence to assist treatment decision-making for RR+ pAML patients.